- 20 apr.- 19:27

Schlumberger comunica i risultati registrati nel primo trimestre del 2018

Business Wire.
  • Utile pari a 7,8 miliardi di dollari, con un calo del 4% in termini sequenziali
  • Reddito d’esercizio al lordo delle imposte pari a 974 milioni di dollari, con un calo del 16% in termini sequenziali
  • Rendimento per azione pari a 0,38 dollari
  • Il flusso di cassa generato dalle operazioni ha raggiunto 568 milioni di dollari
- 20 apr.- 11:05

Schlumberger Announces First-Quarter 2018 Results

Business Wire.
  • Revenue of $7.8 billion decreased 4% sequentially
  • Pretax operating income of $974 million decreased 16% sequentially
  • EPS was $0.38
  • Cash flow from operations was $568 million
- 20 apr.- 10:30

Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases

Business Wire.
  • Transaction builds upon the productive collaboration that produced SPINRAZA® as well as two antisense drug candidates currently in the clinic, with the potential to advance up to seven more drug candidates to the clinic within the next two years
  • The antisense platform developed by Ionis is an established and validated gene-based therapeutic modality, as evidenced by the success of SPINRAZA, with the potential to address numerous neurological diseases that are currently untreatable
  • Biogen will pay Ionis $1 billion in cash, including an equity investment in Ionis stock and an upfront payment, representing one of the most significant discovery stage collaborations in the industry

Video Economia

Vai alla rubrica Risparmio e Investimenti
Vai al sito: ANSA Professioni

Vai al sito: L'Agenda Economica Finanziaria e Rassegna Stampa dell'ANSA

BANCA IFIS

 (ANSA)

Banca Ifis:Osservatorio,in 2017 prezzo transazioni Npl a 18%

Stima intorno a 13mld per un totale 72mld di sofferenze cedute


Vai alla rubrica: Pianeta Camere

Real Estate

Criptovalute news